By Dominic Tyer (European Pharmaceutical Review)2025-09-22T13:55:33
The CHMP hands the cancer drug two new recommendations, and the FDA approves its subcutaneous use as Keytruda Qlex.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-07-25T08:10:00
Sponsored by JRS Pharma and Gattefosse, By European Pharmaceutical Review
2026-05-21T14:00:00 2026-05-21T15:00:00
Sponsored by USP
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
2026-03-26T15:00:00 2026-03-26T16:00:00
Sponsored by Medable
2026-02-09T10:00:00 2026-02-09T11:00:00
Sponsored by Emerson
2025-06-03T13:35:00
Sponsored by bioMérieux, By European Pharmaceutical Review
Site powered by Webvision Cloud